Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 4/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.53 |
| ▸ | GPR132 | Q9UNW8 | 4/20 | 0.51 |
| ▸ | CTSB | P07858 | 3/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | PLAU | P00749 | 1/20 | 0.49 |
| ▸ | PLAT | P00750 | 1/20 | 0.49 |
| ▸ | CMKLR2 | P46091 | 1/20 | 0.48 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20467724 | 1.00 | ITGB3 (0.53) | ITGB3ITGA2BGPR132CTSBCTSS | |
| SCHEMBL5634425 | 0.92 | GPR132 (0.58) | ITGB3ITGA2BGPR132CTSBCTSS | |
| SCHEMBL5634418 | 0.92 | GPR132 (0.58) | ITGB3ITGA2BGPR132CTSBCTSS | |
| SCHEMBL31084239 | 0.92 | GPR132 (0.58) | ITGB3ITGA2BGPR132CTSBCTSS | |
| SCHEMBL8717685 | 0.87 | ITGB3 (0.66) | ITGB3ITGA2BCTSBCTSSCTSK | |
| SCHEMBL7084689 | 0.87 | ITGB3 (0.66) | ITGB3ITGA2BCTSBCTSSCTSK | |
| SCHEMBL20467712 | 0.85 | CTSB (0.48) | CTSBCTSSCTSKCYP3A4F2 | |
| SCHEMBL21671229 | 0.85 | CTSB (0.48) | CTSBCTSSCTSKCYP3A4F2 | |
| SCHEMBL30918338 | 0.84 | CTSL (0.55) | GPR132CTSBCTSSCTSKCTSL | |
| SCHEMBL21643185 | 0.83 | ITGB3 (0.48) | ITGB3ITGA2BGPR132CTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200040372-A1 | METHOD FOR SYNTHESIZING PEPTIDES IN CELL-FREE TRANSLATION SYSTEM | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200040372-A1 | METHOD FOR SYNTHESIZING PEPTIDES IN CELL-FREE TRANSLATION SYSTEM | AARS1, NSUN3, RNGTT | ITGB3 3924/4885ITGA2B 4208/4885GPR132 3742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.